News and Resources
Knopp Biosciences Announces Positive Top-Line Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma
Discover this News
Dexpramipexole Targets Eosinophilic Inflammation
Discover this News
Knopp Biosciences Completes Enrollment in Phase 2 Trial of Oral Dexpramipexole in Eosinophilic Asthma
Discover this News
Knopp Biosciences and University of Leicester Announce Update on Planned Phase 2 Clinical Trial of Oral Dexpramipexole in Severe Eosinophilic Asthma
Discover this News
Dexpramipexole Responsiveness is Increased in Eosinophilic Subjects
Discover this News
Developing Dexpramipexole for the Treatment of Eosinophilic Disorders
Discover this News
Knopp Biosciences to Present Clinical Data for Dexpramipexole at 11th Biennial Symposium of the International Eosinophil Society
Discover this News
Knopp Biosciences Receives FDA Orphan Drug Designation for Dexpramipexole for Treatment of Hypereosinophilic Syndrome
Discover this News
Knopp Biosciences Enters Collaboration with Leading UK Investigators to Commence Phase 2 Clinical Trial of Dexpramipexole in Severe Eosinophilic Asthma
Discover this News
1
2